Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 310 of 5804
-
Experimental 'Body-Made' CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Dengue vaccine trial aims to protect seniors
⭐️ VACCINE ⭐️ Recruiting nowThis is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue vaccine (Dengue 1,2,3,4 (attenuated)) in participants ag…
Phase: PHASE3 • Sponsor: Butantan Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
Could a Vitamin-Like pill stop prediabetes from becoming diabetes?
Prevention Recruiting nowThe goal of this clinical trial is to prevent the change from prediabetes (a pre-stage of type 2 diabetes mellitus (T2DM)) to T2DM in participants with prediabetes using oral CIR-NA (a nicotinic acid formulation that is designed to be released after reaching the ileum) which targ…
Phase: PHASE2 • Sponsor: University Hospital Schleswig-Holstein • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Hormone boost then radiation: new hope for tough prostate cancer?
Disease control Recruiting nowThe purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will tak…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take on tough lung cancer in first human trial
Disease control Recruiting nowThis is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can brain zaps and cycling boost aging minds?
Disease control Recruiting nowThis study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assig…
Phase: NA • Sponsor: Cheng-Hsin General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a simple pill prevent deadly clots in lung cancer patients?
Prevention Not yet recruitingThe aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Prevention
Last updated Jun 26, 2026 14:52 UTC
-
AI spots hidden heart valve disease in routine scans
Diagnosis Recruiting nowThis is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans. The primary objective is to evaluate the model's diagnostic performance, with the sensitivi…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Engineered immune cells take on tough bladder cancer
Disease control Recruiting nowThis hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally advanced or metastatic urothelial carcinoma. Based…
Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
Disease control Recruiting nowThis is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Supercharged immune cells take on deadly brain tumors
Disease control Recruiting nowThis is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-gr…
Phase: PHASE1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, M…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells (EBDTKN-401) after lymphodepleting chemotherapy in adults wit…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Supercharged immune cells take on stubborn esophageal cancer
Disease control Recruiting nowThis example study evaluates the safety, feasibility, cellular kinetics, and preliminary anti-tumor activity of EBNK-1822H2, an illustrative allogeneic cord blood-derived dual-target CAR-NK cell product directed against CLDN18.2 and HER2, in adults with relapsed/refractory or met…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New shot could help sleep apnea patients breathe easier and shed pounds
Disease control Recruiting nowThe aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
Phase: PHASE3 • Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Sharper radiation beams aim to improve prostate cancer outcomes
Disease control Recruiting nowThe aim of this clinical trial is to evaluate the efficacy of adaptive prostate Stereotatic Body RadioTherapy (SBRT), which integrates both Whole Pelvic RadioTherapy (WPRT) and dose escalation on the Dominant Intraprostatic Lesion (DIL), compared with standard radiotherapy. This …
Phase: NA • Sponsor: Center Eugene Marquis • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor \[CAR\] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or has not responde…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Experimental combo targets Hard-to-Treat colorectal liver metastases
Disease control Not yet recruitingAn open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Virus and chemo combo takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: targeted drug enters human trials
Disease control Recruiting nowThis is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.
Phase: PHASE1, PHASE2 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC